von Willebrand factor or factor VIII and von Willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes

US8603979B2 · kind B2 · utility

Assignee

• CSL Behring AG · DE

Inventors

• Gerhard Dickneite · Marburg, DE
• Ingo Pragst · Marburg, DE
• Henrique Lessa · Cologne, DE
• Thorsten Haas · Oberperfuss, AT
• Stefan Zeitler · Reifenthal, DE

Key dates

• Filing date: Jul 10, 2009
• Grant date: Dec 10, 2013
• Expiry date: Apr 7, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P7/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a von Willebrand Factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-Willebrand-Factor (vWF) to a patient in need thereof. The present invention also relates to a composition comprising vWF and a composition comprising FVIII for simultaneous, separate or sequential use for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes.